LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 158

Search options

  1. Book: Best practice for the assessment of measurable residual disease (MRD) in multiple myeloma

    Bal, Susan / Costa, Luciano J.

    (Clinical advances in hematology & oncology : Clinical roundtable monograph ; volume 18, issue 1, supplement 1 (January 2020))

    2020  

    Author's details discussants Susan Bal, MD, Luciano J. Costa, MD, PhD
    Series title Clinical advances in hematology & oncology : Clinical roundtable monograph ; volume 18, issue 1, supplement 1 (January 2020)
    Clinical advances in hematology & oncology
    Clinical advances in hematology & oncology
    Collection Clinical advances in hematology & oncology
    Clinical advances in hematology & oncology
    Language English
    Size 44 Seiten, Illustrationen
    Publisher Millennium Medical Publishing
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT020952724
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 6505 -18,Suppl.1- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Insights into the assessment of measurable residual disease (MRD) in patients with multiple myeloma.

    Costa, Luciano J

    Clinical advances in hematology & oncology : H&O

    2021  Volume 18 Suppl 1, Issue 1, Page(s) 11–16

    MeSH term(s) Flow Cytometry ; Humans ; Multiple Myeloma/blood ; Multiple Myeloma/therapy ; Neoplasm, Residual
    Language English
    Publishing date 2021-04-12
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Bridging treatment prior to chimeric antigen receptor T-cell therapy in multiple myeloma.

    Bal, Susan / Costa, Luciano J

    British journal of haematology

    2023  Volume 204, Issue 2, Page(s) 449–454

    Abstract: Autologous patient-derived adoptive T-cell therapies have revolutionized the management of relapsed multiple myeloma (MM). However, the current manufacturing and quality control processes result in lengthy vein-to-vein time, making bridging therapy ... ...

    Abstract Autologous patient-derived adoptive T-cell therapies have revolutionized the management of relapsed multiple myeloma (MM). However, the current manufacturing and quality control processes result in lengthy vein-to-vein time, making bridging therapy necessary for most patients. Yet the decision and choice of optimal bridging therapy are complex in the heavily pretreated relapsed MM patient. In this perspective piece, the authors provide their approach and considerations while selecting an optimal bridging regimen before autologous chimeric antigen receptor T-cell therapy.
    MeSH term(s) Humans ; Receptors, Chimeric Antigen ; Multiple Myeloma/therapy ; T-Lymphocytes ; Immunotherapy, Adoptive/adverse effects ; Cell- and Tissue-Based Therapy ; B-Cell Maturation Antigen
    Chemical Substances Receptors, Chimeric Antigen ; B-Cell Maturation Antigen
    Language English
    Publishing date 2023-11-30
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.19227
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.182: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast.

    Costa, Luciano J / Rodriguez-Otero, Paula

    Advances in therapy

    2024  

    Abstract: Immunotherapies have significantly improved outcomes in patients with multiple myeloma yet maintaining a durable response in heavily pretreated patients remains challenging. Therapies that target B cell maturation antigen (BCMA) provide additional ... ...

    Abstract Immunotherapies have significantly improved outcomes in patients with multiple myeloma yet maintaining a durable response in heavily pretreated patients remains challenging. Therapies that target B cell maturation antigen (BCMA) provide additional treatment options in patients whose disease becomes refractory to several drug classes in early lines of therapy. Clinical trial data from selected patient populations and controlled settings are complemented by real-world data (RWD) from actual clinical practice. In this podcast, the authors reviewed and discussed seven abstracts presented at the 65th Annual Meeting of the American Society of Hematology, focusing on BCMA-directed therapies, emphasizing the value of RWD in treatment decision-making, and suggesting how RWD can help advance multiple myeloma research. These abstracts include real-world outcome studies in patients with relapsed or refractory multiple myeloma with triple-class exposed or refractory disease (abstracts 542, 3358, and 6727); an analysis on disease burden associated with delayed diagnosis (abstract 3771); comparability of real-world outcomes vs clinical trial data (abstracts 91 and 545); and outcomes in patients with multiple myeloma who experienced early treatment failure after upfront quadruplet therapy (abstract 1989).Podcast available for this article.
    Language English
    Publishing date 2024-04-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 632651-1
    ISSN 1865-8652 ; 0741-238X
    ISSN (online) 1865-8652
    ISSN 0741-238X
    DOI 10.1007/s12325-024-02842-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2101: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Clinical trial material.

    Costa, Luciano J

    The Lancet. Haematology

    2020  Volume 7, Issue 5, Page(s) e368

    Language English
    Publishing date 2020-05-03
    Publishing country England
    Document type Journal Article
    ISSN 2352-3026
    ISSN (online) 2352-3026
    DOI 10.1016/S2352-3026(20)30118-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Bispecific T-cell engagers for treatment of multiple myeloma.

    Ravi, Gayathri / Costa, Luciano J

    American journal of hematology

    2022  Volume 98 Suppl 2, Page(s) S13–S21

    Abstract: Bispecific T cell engagers (TCE) derive from monoclonal antibodies and concomitantly engage a target on the surface of cancer cell and CD3 on the surface of T-cells. TCEs promote T cell activation and lysis of tumor cells. Most TCEs in development for ... ...

    Abstract Bispecific T cell engagers (TCE) derive from monoclonal antibodies and concomitantly engage a target on the surface of cancer cell and CD3 on the surface of T-cells. TCEs promote T cell activation and lysis of tumor cells. Most TCEs in development for multiple myeloma (MM) target the B cell maturation antigen (BCMA) and differ among themselves in structure, pharmacokinetics, route and schedule of administration. CD3/BCMA TCEs produce response in ~60% of patients treated in phase 1 trials. TCEs are also in development targeting the G protein-coupled receptor, class C group 5 member D (GPRC5D) and the Fc receptor homologue 5 (FcRH5). Main toxicities are cytokine release syndrome and cytopenias. Here we review the current development and future directions of TCEs in MM.
    MeSH term(s) Humans ; T-Lymphocytes ; Antibodies, Bispecific/therapeutic use ; Multiple Myeloma/drug therapy ; B-Cell Maturation Antigen ; Antibodies, Monoclonal
    Chemical Substances Antibodies, Bispecific ; B-Cell Maturation Antigen ; Antibodies, Monoclonal
    Language English
    Publishing date 2022-06-28
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.26628
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1251: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy.

    Bal, Susan / Costa, Luciano J

    The Lancet. Haematology

    2021  Volume 8, Issue 6, Page(s) e386–e387

    MeSH term(s) Dexamethasone ; Disease-Free Survival ; Humans ; Lenalidomide/therapeutic use ; Multiple Myeloma/drug therapy ; Neoplasm, Residual
    Chemical Substances Dexamethasone (7S5I7G3JQL) ; Lenalidomide (F0P408N6V4)
    Language English
    Publishing date 2021-05-28
    Publishing country England
    Document type Journal Article ; Comment
    ISSN 2352-3026
    ISSN (online) 2352-3026
    DOI 10.1016/S2352-3026(21)00140-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article: Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.

    Bal, Susan / Costa, Luciano J

    Clinical advances in hematology & oncology : H&O

    2021  Volume 18 Suppl 1, Issue 1, Page(s) 1–20

    Abstract: Therapeutic advances in multiple myeloma have led to durable, deep remissions in a subset of patients. However, outcomes of patients achieving a complete response are not homogeneous. In recent years, measurable residual disease (MRD) has emerged as a ... ...

    Abstract Therapeutic advances in multiple myeloma have led to durable, deep remissions in a subset of patients. However, outcomes of patients achieving a complete response are not homogeneous. In recent years, measurable residual disease (MRD) has emerged as a prognostic biomarker. While several technologies have been evaluated to detect MRD, two assessment technologies are most frequently utilized in patients with multiple myeloma. Next-generation flow (NGF) uses flow cytometry to identify malignant plasma cells through the presence of immunologic markers located on the cell surface. Next-generation sequencing (NGS) analyzes for the presence of sequences in immunoglobulin genes that were previously identified as markers of that specific patient's plasma cell malignant clone. Both methods are included in criteria for MRD by the International Myeloma Working Group, which defines MRD negativity as less than 10
    MeSH term(s) Clinical Trials as Topic ; Flow Cytometry ; High-Throughput Nucleotide Sequencing ; Humans ; Immunoglobulins/genetics ; Multiple Myeloma/diagnosis ; Multiple Myeloma/genetics ; Neoplasm, Residual/diagnosis ; Neoplasm, Residual/genetics ; Plasma Cells/pathology ; Prognosis
    Chemical Substances Immunoglobulins
    Language English
    Publishing date 2021-04-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma: further observations.

    Costa, Luciano J / Bal, Susan

    Clinical advances in hematology & oncology : H&O

    2021  Volume 18 Suppl 1, Issue 1, Page(s) 17

    MeSH term(s) Disease Progression ; Flow Cytometry ; Humans ; Multiple Myeloma/blood ; Multiple Myeloma/therapy ; Neoplasm, Residual
    Language English
    Publishing date 2021-04-12
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Teclistamab in patients with multiple myeloma and impaired renal function.

    Joiner, Laura / Bal, Susan / Godby, Kelly N / Costa, Luciano J

    American journal of hematology

    2023  Volume 98, Issue 11, Page(s) E322–E324

    Abstract: Robust anti-myeloma activity with teclistamab in patients with severe renal impairment. ...

    Abstract Robust anti-myeloma activity with teclistamab in patients with severe renal impairment.
    Language English
    Publishing date 2023-08-23
    Publishing country United States
    Document type Letter
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.27063
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1251: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top